Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKTXNASDAQ:BLPHNASDAQ:FCSCNASDAQ:GTXINASDAQ:INNT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.17-1.4%$1.79$1.08▼$5.50$9.29M0.9612,037 shs2,647 shsBLPHBellerophon Therapeutics$0.06+0.2%$0.05$0.03▼$11.15$674K0.6759,888 shs889 shsFCSCFibrocell Science$3.00$3.00$1.45▼$3.28$29.28M1.6778,673 shsN/AGTXIGTX$8.25-3.4%$4.77$0.74▼$25.60$198.41M2.22390,540 shs6,862 shsINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shs5 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%-1.65%-36.02%-55.01%-68.68%BLPHBellerophon Therapeutics+1.66%-3.68%-4.75%-9.84%-99.26%FCSCFibrocell Science0.00%0.00%0.00%0.00%0.00%GTXIGTX-3.45%-4.07%+2.43%-8.03%+2,438.46%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.89%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABLPHBellerophon Therapeutics2.1848 of 5 stars3.00.00.04.83.20.00.6FCSCFibrocell ScienceN/AN/AN/AN/AN/AN/AN/AN/AGTXIGTXN/AN/AN/AN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari TherapeuticsN/AN/AN/AN/ABLPHBellerophon Therapeutics2.00Hold$2.003,529.76% UpsideFCSCFibrocell ScienceN/AN/AN/AN/AGTXIGTXN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/AFCSCFibrocell Science$350K83.66N/AN/A$0.98 per share3.06GTXIGTXN/AN/AN/AN/A$1.09 per shareN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A5/6/2024 (Estimated)BLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)FCSCFibrocell Science-$10.28M-$1.45N/AN/AN/AN/A23.10%10.56%N/AGTXIGTX-$38.42M-$1.65N/AN/AN/AN/A-104.19%-86.42%N/AINNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/ALatest GTXI, AKTX, BLPH, FCSC, and INNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/26/2024N/ABLPHBellerophon TherapeuticsN/A-$0.42-$0.42N/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/AGTXIGTXN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.950.95BLPHBellerophon TherapeuticsN/A3.963.96FCSCFibrocell Science0.475.095.09GTXIGTXN/A12.3912.39INNTInnovate BiopharmaceuticalsN/A0.350.35OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%BLPHBellerophon Therapeutics10.61%FCSCFibrocell Science36.72%GTXIGTX9.50%INNTInnovate Biopharmaceuticals5.88%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics61.80%BLPHBellerophon Therapeutics5.20%FCSCFibrocell Science1.10%GTXIGTX40.90%INNTInnovate Biopharmaceuticals7.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics97.92 million3.03 millionNot OptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableFCSCFibrocell Science199.76 millionN/AOptionableGTXIGTX2124.05 millionN/ANot OptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableGTXI, AKTX, BLPH, FCSC, and INNT HeadlinesSourceHeadlineInnovate Mississippi’s CoBuilders program returns to Oxfordoxfordeagle.com - April 25 at 3:57 PMCelebrating 40 years of innovation: NCBiotech and NC’s life sciences sectorncbiotech.org - April 24 at 2:31 PMBiopharmaceuticals Market Expansion: Anticipated To Reach USD 566 Billion By 2033, Reflecting A 8.2% Growth Ratepharmiweb.com - April 24 at 9:30 AMCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the LSX World Congress 2024finanznachrichten.de - April 23 at 10:45 AMLand Development Agency first patron of UG based Construct Innovategalwaybayfm.ie - April 22 at 2:23 PMSystImmune, Inc. Appoints Dr. Jie D'Elia as Chief Executive Officerfinance.yahoo.com - April 22 at 9:23 AMStuart Therapeutics, Inc. Announces Upcoming Presentations at ARVO 2024valdostadailytimes.com - April 19 at 1:33 PMInnovate Change - best online casinos review by the experts 2024msn.com - April 19 at 8:33 AMMyOpNotes secures Innovate UK grant funding to support expansiondigitalhealth.net - April 19 at 8:33 AMInnovate UK and British Business Bank sign Memorandum of Understandingassetfinanceinternational.com - April 18 at 10:16 AMOcular Therapeutix, Inc.: Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathyfinanznachrichten.de - April 18 at 10:16 AMBiopharma Plastics: Innovation in Healthcare Packaging for a US$ 15.95 Billion Growth Opportunity by 2033fmiblog.com - April 18 at 10:16 AMIngredion names new chief innovation officerbakingbusiness.com - April 17 at 1:48 PMInnovate UK and British Business Bank Sign MoU With Aim to Support Business Growthcrowdfundinsider.com - April 17 at 8:48 AMInnovative startups are changing the landscape of health impact everywhere. Are investors aware?impactalpha.com - April 17 at 8:48 AMMOBILion Systems, Inc. Expands European Presence to Support MOBIE Instrument Sales and Customer Successprnewswire.co.uk - April 16 at 10:11 AMInnovate UK: New agri-tech centre launches in Aprilsciencebusiness.net - April 16 at 10:11 AMThird Harmonic Bio Inc CEO Natalie Holles Sells 13,558 Sharesfinance.yahoo.com - April 15 at 7:13 PMAmerican Thoracic Society Selects Vasomune Therapeutics, Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summitfinance.yahoo.com - April 15 at 8:58 AMUniversity of Phoenix Office of Educational Equity Leadership Presents at 2024 OLC Innovate Conferencetmcnet.com - April 12 at 9:52 AMSouthern Ocean Chamber Of Commerce Innovate & Caffeinate Breakfastjerseyshoreonline.com - April 10 at 4:59 PMMonopar Therapeutics Inc.: Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patientsfinanznachrichten.de - April 10 at 11:58 AMInnovate Change NZ: Guide into Best High-Payout Online Casinossiliconvalley.com - April 10 at 11:58 AMIN8bio, Inc: IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024finanznachrichten.de - April 10 at 6:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Bellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Fibrocell ScienceNASDAQ:FCSCFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.GTXNASDAQ:GTXIGTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.Innovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.